Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' reply

Affiliations

• ¹ Department of Gastroenterology, CHU Pontchaillou, Rennes, France; University of Rennes 1, Rennes, France; INSERM U1242, Oncogenesis, Stress & Signaling, Rennes, France. Electronic address: [email protected].
• ² University of Lorraine, Nancy, France; CNRS UMR7039 CRAN, Vandoeuvre-lès-Nancy, France; Biopathology Department, Cancer Institute of Lorraine, Vandoeuvre-lès-Nancy, France.
• ³ Pathology Department, CHU Charles Nicolle, Rouen, France; Inserm 1079, University of Normandy, Rouen, France.
• ⁴ Department of Digestive Oncology, Jean Mermoz Hospital, Lyon, France.
• ⁵ UMRS-1174 Personnalized Medicine, Pharmacogenomic, Therapeutic Optimization, Paris Descartes University, Paris, France; Department of Biology, Georges Pompidou European Hospital, Paris, France.
• ⁶ Department of Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.